DrugPatentWatch Database Preview

Exelixis Company Profile

« Back to Dashboard

What is the competitive landscape for EXELIXIS, and when can generic versions of EXELIXIS drugs launch?

EXELIXIS has two approved drugs.

There are five US patents protecting EXELIXIS drugs.

There are one hundred and thirty-six patent family members on EXELIXIS drugs in twenty-eight countries and twelve supplementary protection certificates in nine countries.

Summary for Exelixis

International Patents:	136
US Patents:	5
Tradenames:	2
Ingredients:	1
NDAs:	2

Drugs and US Patents for Exelixis

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-001	Apr 25, 2016		RX	Yes	No	8,877,776		Y	Y
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-002	Apr 25, 2016		RX	Yes	No	9,724,342		Y
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-001	Apr 25, 2016		RX	Yes	No
Exelixis	COMETRIQ	cabozantinib s-malate	CAPSULE;ORAL	203756-002	Nov 29, 2012		RX	Yes	No
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-001	Apr 25, 2016		RX	Yes	No	7,579,473		Y	Y
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-002	Apr 25, 2016		RX	Yes	No	8,497,284

Non-Orange Book US Patents for Exelixis

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
9,809,549	Malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'(4-fluorophenyl)cycl- opropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
2,014,155,378
9,174,947	c-Met modulators and methods of use
8,178,532	c-Met modulators and method of use
8,067,436	c-Met modulators and methods of use
8,476,298	c-Met modulators and method of use

International Patents for Exelixis Drugs

Country	Document Number	Estimated Expiration
Japan	2017160270
Mexico	2013009116
South Korea	20120013301
San Marino	T201300050
Hong Kong	1164312
Australia	2013204031

Supplementary Protection Certificates for Exelixis Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2014033,C2213661	Lithuania		PRODUCT NAME: KABOZANTINIBAS IR JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140321
0 50007-2014	Slovakia		PRODUCT NAME: CABOZANTINIB; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140326
2014000091	Germany		PRODUCT NAME: CABOZANTINIB UND JEDES THERAPEUTISCHE AEQUIVALENT HIERVON WIE DURCH DAS GRUNDPATENT GESCHUETZT, EINSCHLIESSLICH PHARMAZEUTISCH ANNEHMBARER SALZE; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140321
0678	Netherlands		PRODUCT NAME: CABOZANTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140326
2014 00039	Denmark		PRODUCT NAME: CABOZANTINIB, INKLUSIVE FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER CABOZANTINIB (S)-MALAT; REG. NO/DATE: EU/1/13/890/001-003 20140321
2014 00039	Denmark		PRODUCT NAME: CABOZANTINIB, INKLUSIVE FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER CABOZANTINIB (S)-MALAT; REG. NO/DATE: EU/1/13/890/001-003 20140326

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Exela Holdings
• Exela Pharma Science
• Exela Pharma Scs Llc
• Exelixis
• Exelixis Inc
• Exeltis Usa Inc